El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 

RTS,S/AS02A malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infection

dc.contributor.authorEnosse, Soniacat
dc.contributor.authorDobaño, Carlota, 1969-cat
dc.contributor.authorQuelhas, Dianacat
dc.contributor.authorAponte, John J.cat
dc.contributor.authorLievens, Marccat
dc.contributor.authorLeach, Amandacat
dc.contributor.authorSacarlal, Jahitcat
dc.contributor.authorGreenwood, Briancat
dc.contributor.authorMilman, Jessicacat
dc.contributor.authorDubovsky, Filipcat
dc.contributor.authorCohen, Joecat
dc.contributor.authorThompson, Ricardocat
dc.contributor.authorBallou, W. Ripleycat
dc.contributor.authorAlonso, Pedrocat
dc.contributor.authorConway, David J.cat
dc.contributor.authorSutherland, Colin J.cat
dc.date.accessioned2011-10-20T08:34:42Z
dc.date.available2011-10-20T08:34:42Z
dc.date.issued2006
dc.description.abstractObjective: The candidate malaria vaccine RTS,S/AS02A is a recombinant protein containing part of the circumsporozoite protein (CSP) sequence of Plasmodium falciparum, linked to the hepatitis B surface antigen and formulated in the proprietary adjuvant system AS02A. In a recent trial conducted in children younger than age five in southern Mozambique, the vaccine demonstrated significant and sustained efficacy against both infection and clinical disease. In a follow-up study to the main trial, breakthrough infections identified in the trial were examined to determine whether the distribution of csp sequences was affected by the vaccine and to measure the multiplicity of infecting parasite genotypes. Design: P. falciparum DNA from isolates collected during the trial was used for genotype studies. Setting: The main trial was carried out in the Manhiça district, Maputo province, Mozambique, between April 2003 and May 2004. Participants: Children from the two cohorts of the main trial provided parasite isolates as follows: children from Cohort 1 who were admitted to hospital with clinical malaria; children from Cohort 1 who were parasite-positive in a cross-sectional survey at study month 8.5; children from Cohort 2 identified as parasite-positive during follow-up by active detection of infection. Outcome: Divergence of DNA sequence encoding the CSP T cell-epitope region sequence from that of the vaccine sequence was measured in 521 isolates. The number of distinct P. falciparum genotypes was also determined. Results: We found no evidence that parasite genotypes from children in the RTS,S/AS02A arm were more divergent than those receiving control vaccines. For Cohort 1 (survey at study month 8.5) and Cohort 2, infections in the vaccine group contained significantly fewer genotypes than those in the control group, (p 1/4 0.035, p 1/4 0.006), respectively, for the two cohorts. This was not the case for children in Cohort 1 who were admitted to hospital (p 1/4 0.478). Conclusions: RTS,S/AS02A did not select for genotypes encoding divergent T cell epitopes in the C-terminal region of CSP in this trial. In both cohorts, there was a modest reduction in the mean number of parasite genotypes harboured by vaccinated children compared with controls, but only among those with asymptomatic infections.eng
dc.format.extent10 p.-
dc.format.mimetypeapplication/pdf-
dc.identifier.idgrec573132
dc.identifier.issn1555-5887
dc.identifier.pmid16871327
dc.identifier.urihttps://hdl.handle.net/2445/20344
dc.language.isoengeng
dc.publisherPLoS
dc.relation.isformatofReproducció digital del document publicat a: http://dx.doi.org/10.1371/journal.pctr.0010005cat
dc.relation.ispartofPlos Clinical Trials, 2006, 1(1): e5
dc.relation.urihttp://dx.doi.org/10.1371/journal.pctr.0010005
dc.rightscc-by, (c) Enosse, S. et al., 2006
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/2.5/
dc.sourceArticles publicats en revistes (Medicina)
dc.subject.classificationVacunaciócat
dc.subject.classificationVacuna de la malàriacat
dc.subject.classificationMedicina preventivacat
dc.subject.classificationMoçambiccat
dc.subject.otherVaccinationeng
dc.subject.otherMalaria vaccineeng
dc.subject.otherPreventive medicineeng
dc.subject.otherMozambiqueeng
dc.titleRTS,S/AS02A malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infectioneng
dc.typeinfo:eu-repo/semantics/articleeng
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
573132.pdf
Mida:
724.21 KB
Format:
Adobe Portable Document Format